Tag: licensing
-
GE Develops 500 Gigabyte Micro-Holographic Disc
The technology research division of General Electric Co. says it successfully demonstrated an optical storage technology using micro-holographic material that can support data recording at the same speed as Blu-ray discs. The technology will be discussed today at IEEE’s Joint International Symposium on Optical Memory & Optical Data Storage Topical Meeting in Kauai, Hawaii. GE…
-
Sanofi, Rib-X to Collaborate on New Types of Antibiotics
The global pharmaceutical firm Sanofi has agreed to jointly develop new antibiotic technology with the biotechnology company Rib-X Pharmaceuticals in New Haven, Connecticut. The agreement includes an option for Sanofi to license the technology from Rib-X that treats resistant pathogens. Rib-X’s RX-04 program is developing new types of antibiotics aimed at drug-resistant pathogens, which the…
-
Prof. Develops Anti-Microbial Technology for Fabrics
A University of Georgia researcher has invented an anti-microbial technology that can turn medical linens and clothing germ-free. Jason Locklin (right), a member of the chemistry and engineering faculties at the university’s Athens campus, published results of his and colleagues’ research last month in the journal ACS Applied Materials & Interfaces; paid subscription required. Locklin’s discovery…
-
Challenges Focus on Quantification, Measurements of Metals
Two challenges posted today (30 June) on InnoCentive seek solutions to problems involving quantification or measurements of properties of metals. InnoCentive, in Waltham, Massachusetts, is a company that conducts challenge competitions for sponsors, who for these challenges have decided to remain anonymous. One of today’s challenges seeks a method for in-line quantification and real-time reporting…
-
Pharmas, BioPontis Alliance Partner on Translational Science
BioPontis Alliance, a hybrid investment fund and product development company in Raleigh, North Carolina, and global pharmaceutical company Pfizer Inc. agreed to collaborate on translational technology development supported by BioPontis. The companies announced the deal at the 2011 BIO International Convention in Washington, D.C. BioPontis establishes research alliances with academic-research institutes, where BioPontis searches for…
-
Neuromuscular Drug Gets Fast-Track, Orphan Approval
Repligen Corp. in Waltham, Massachusetts says its drug candidate for spinal muscular atrophy received fast-track and orphan drug status from U.S. and European regulators. The U.S. Food and Drug Administration (FDA) granted fast-track status to Repligen’s RG3039, while the European Medicines Agency gave the drug its orphan medicinal product designation. Spinal muscular atrophy (SMA) is…
-
Pain Killer with Built-in Abuse Deterrence Gets FDA Clearance
A prescription pain killing drug developed by Pfizer Inc. in New York and Acura Pharmaceuticals Inc. in Palatine, Illinois has received marketing approval from the U.S. Food and Drug Administration. Oxecta, an opioid analgesic tablet made from oxycodone hydrochloride (HCl), contains ingredients developed by Acura Pharmaceuticals to deter tampering that leads to misuse or abuse…
-
Imaging Technology Used to Improve Grain Yields
Scientists at University of Adelaide in Australia are developing a technology based on computer imaging to better understand growth patterns of cereal grains and improve their yields under various conditions. The project involves a collaboration among computer scientists and plant physiologists at the university, with a German computer-imaging company. The team aims to develop technology…
-
Audion, Sanofi to Partner on Hearing Loss Therapies
The French pharmaceutical company Sanofi and biotechnology company Audion Therapeutics in Amsterdam have agreed to develop potential treatments for hearing loss through through regenerative medicine and biologics. The collaboration will build on technology developed by Audion’s co-founder Albert Edge at the Massachusetts Eye and Ear Infirmary in Boston. Audion originally licensed Edge’s technology from Mass…
-
Lilly Spins Off Biotech to Develop Sepsis Drug
Eli Lilly and Company in Indianapolis, Indiana has signed agreements with private investors Care Capital and NovaQuest Capital to establish BioCritica Inc., a new biotechnology company. BioCritica will initially focus on the continued U.S. development and commercialization of Xigris — drotrecogin alfa (activated) — Lilly’s medicine for severe sepsis. Under the agreement, BioCritica will acquire…